We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+2.15%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$843M
AUM Growth
+$92.2M
Cap. Flow
+$126M
Cap. Flow %
14.96%
Top 10 Hldgs %
33.86%
Holding
109
New
20
Increased
44
Reduced
26
Closed
18

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$21.4M
2
CVS icon
CVS Health
CVS
+$19M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.7M
4
RVTY icon
Revvity
RVTY
+$16.1M
5
UNH icon
UnitedHealth
UNH
+$15.4M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$27.5M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$20.3M
3
ABT icon
Abbott
ABT
+$20M
4
GILD icon
Gilead Sciences
GILD
+$16.1M
5
BSX icon
Boston Scientific
BSX
+$11.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RPID icon
76
Rapid Micro Biosystems
RPID
$84.8M
$1.94M 0.23%
+735,621
New +$1.68M
VERA icon
77
Vera Therapeutics
VERA
$2.16B
$1.83M 0.22%
+76,125
New +$2.45M
APGE icon
78
Apogee Therapeutics
APGE
$10.2B
$1.74M 0.21%
46,663
-38,337
-45% -$1.48M
ICAD
79
DELISTED
iCAD Inc
ICAD
$1.61M 0.19%
+781,670
New +$1.99M
MRVI icon
80
Maravai LifeSciences
MRVI
$861M
$1.46M 0.17%
660,000
+310,000
+89% +$1.22M
UPB
81
Upstream Bio Inc
UPB
$378M
$1.43M 0.17%
+233,563
New +$2.23M
MRUS
82
DELISTED
Merus
MRUS
$1.19M 0.14%
28,230
-17,450
-38% -$761K
SLN
83
Silence Therapeutics
SLN
$641M
$1.13M 0.13%
401,746
-89,334
-18% -$436K
ORIC icon
84
Oric Pharmaceuticals
ORIC
$1.43B
$1.13M 0.13%
+203,006
New +$1.78M
ARDX icon
85
Ardelyx
ARDX
$1.03B
$1.03M 0.12%
209,581
+31,787
+18% +$171K
ENTX icon
86
Entera Bio
ENTX
$138M
$747K 0.09%
439,632
+25,900
+6% +$56.4K
ANNX icon
87
Annexon
ANNX
$873M
$678K 0.08%
351,436
+20,587
+6% +$68.5K
RLAY icon
88
Relay Therapeutics
RLAY
$4.4B
$493K 0.06%
188,052
-312,496
-62% -$1.22M
YARW
89
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
$344K 0.04%
4,360
+1,301
+43% +$160K
FOCL
90
EDAP TMS S.A.
FOCL
$178M
$303K 0.04%
154,832
– –
IRWD icon
91
Ironwood Pharmaceuticals
IRWD
$714M
$301K 0.04%
205,086
-203,449
-50% -$485K
ABT icon
92
Abbott
ABT
$192B
– –
-176,994
Closed -$20M
ARVN icon
93
Arvinas
ARVN
$580M
– –
-106,871
Closed -$2.05M
BCYC
94
Bicycle Therapeutics
BCYC
$284M
– –
-352,481
Closed -$4.93M
BFLY icon
95
Butterfly Network
BFLY
$2.52B
– –
-750,000
Closed -$2.34M
ETON icon
96
Eton Pharmaceutcials
ETON
$1.14B
– –
-276,890
Closed -$3.69M
ICLR icon
97
Icon
ICLR
$12.9B
– –
-15,874
Closed -$3.33M
JAZZ icon
98
Jazz Pharmaceuticals
JAZZ
$16.2B
– –
-37,751
Closed -$4.65M
LFST icon
99
Lifestance Health
LFST
$4.67B
– –
-277,471
Closed -$2.04M
MLTX icon
100
MoonLake Immunotherapeutics
MLTX
$1.47B
– –
-54,294
Closed -$2.94M
1 2 3
4
5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Parkman Healthcare Partners held 109 positions worth $843M, up 12% from $751M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Parkman Healthcare Partners deployed $126M of net new capital in Q1 2025, opening 20 new positions and adding to 44 existing holdings. Its largest new stake was Zimmer Biomet: 200,500 shares worth $22.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Verona Pharma, an estimated $27.5M trimmed.

  • Parkman Healthcare Partners's largest Q1 2025 buy was Zimmer Biomet: 200,500 shares worth $22.7M.
  • Parkman Healthcare Partners added most to CVS Health in Q1 2025, an estimated $19M increase.
  • Parkman Healthcare Partners's biggest Q1 2025 reduction was Verona Pharma, cutting an estimated $27.5M.
  • Parkman Healthcare Partners fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $20.3M.
  • Parkman Healthcare Partners's ten largest holdings make up 34% of its $843M portfolio in Q1 2025.
  • Parkman Healthcare Partners opened 20 new positions and closed 18 in Q1 2025.
  • Parkman Healthcare Partners's portfolio value rose 12% quarter-over-quarter to $843M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2025, filed 15 May 2025.